Innoviva, Inc. (INVA) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 9 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Nov 4, 2026after close 35 8-K
Q2 FY2026Wed, Aug 5, 2026after close 36 8-K
Q1 FY2026Wed, May 6, 2026after close 36 8-K
Q4 FY2025Wed, Feb 25, 2026after close 56 8-K
Q3 FY2025Wed, Nov 5, 2025after close 36 8-K
Q2 FY2025Wed, Aug 6, 2025after close 37 8-K
Q1 FY2025Wed, May 7, 2025after close 37 8-K
Q4 FY2024Wed, Feb 26, 2025after close 57 8-K

What they guided beta

Q3 FY2026 "“IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales." exhibit
Q3 FY2026 "Total revenue: $106.1 million, decreased modestly by 1.6% year over year compared to $107.8 million for the third quarter of 2025, as growth in U.S. net product sales was partially offset with lower royalty revenue and fluctuations in the timing of inventory sales to ex-U.S. partners." exhibit
Q3 FY2026 "Updated 2026 guidance from the Infectious Diseases Society of America (IDSA) further strengthens the clinical positioning of XACDURO ® (sulbactam/durlobactam for injection), reaffirming its use with imipenem or meropenem as the preferred treatment for invasive carbapenem-resistant Acinetobacter baumannii (CRAB) infections." exhibit
Q3 FY2026 "Since inception, and through the end of the third quarter, the Company has repurchased 3,829,116 shares for $82.7 million, reflecting the Company’s continued confidence in its intrinsic value and long-term outlook." exhibit
Q2 FY2026 "We remain on track to achieve at least $150 million in IST U.S. net product sales in 2026, reflecting the differentiation of our marketed critical care and infectious disease portfolio and robust execution,” said Pavel Raifeld, Chief Executive Officer of Innoviva." exhibit
Q2 FY2026 "Since inception, and through the end of the second quarter, the Company has repurchased 2,602,168 shares for $56.4 million, reflecting the Company’s continued confidence in its intrinsic value and long-term outlook." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/INVA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/INVA

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

INVA earnings date badge

HTML

<a href="https://veritasdata.dev/company/INVA/"><img src="https://veritasdata.dev/embed/INVA.svg" alt="INVA earnings date" width="240" height="56"></a>

Markdown

[![INVA earnings date](https://veritasdata.dev/embed/INVA.svg)](https://veritasdata.dev/company/INVA/)

Script

<script async src="https://veritasdata.dev/embed/INVA.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/INVA"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.